How BIEL Shareholders Benefit by Implementing the SofPulse Model
1. Shareholders Receive a Spin‑Off Dividend
A new private subsidiary (e.g., “BIEL Clinical”) would issue shares directly to existing BIEL shareholders.
You would own:
Your current OTC BIEL shares
Plus equity in a new, clean‑cap‑table company valued far higher
This is the same mechanism SofPulse used to unlock value.
2. Massive Valuation Arbitrage (12× Upside Potential)
OTC values BIEL at ~$8.6M.
SofPulse proved PEMF companies can be valued at $100M+ in private markets.
A spin‑off lets BIEL reprice its assets away from the depressed OTC environment.
Shareholders benefit because the underlying IP is suddenly valued at private‑market multiples.
3. Clean Cap Table = Institutional Money
BIEL’s 24.7B shares block any NASDAQ uplist.
A spin‑off starts fresh with something like 20M shares, instantly investable.
Institutions, family offices, and med‑tech funds will not touch a 25B‑share OTC ticker—but they will invest in a clean, AI‑ready clinical subsidiary.
4. High‑Value Verticals Increase Shareholder Upside
The page highlights two divisions that command premium valuations:
Canine Osteoarthritis (fast‑growing, $800M+ market)
Neurological Recovery / Phantom Limb Pain
Spinning these into a focused entity gives shareholders exposure to markets valued far above consumer retail patches.
5. Clinical Data Supports a $100M+ Valuation
Shareholders benefit because BIEL already has the “hard science” needed to justify a premium valuation:
Stanford Hand Arthritis Study (2025) showed statistically significant pain reduction (p=0.02).
Canine OA studies (2024–2025) position BIEL as a competitor to high‑priced biologics like Librela—without the side‑effects.
This clinical foundation is exactly what private investors pay up for.
6. Crowdfunding Becomes a Growth Engine
SofPulse raised $201k+ by pitching a mission (“ending opioid addiction”).
BIEL has 500,000+ users—a built‑in investor base.
Shareholders benefit because crowdfunding:
Raises capital without toxic dilution
Establishes a high private valuation
Creates a marketing flywheel for the new entity
7. The Narrative Shift Boosts Valuation
Right now, BIEL is valued like a company selling $30 patches.
The spin‑off reframes the story as:
“A $1.25B annual reimbursement opportunity in hospitals and insurance.”
That’s the kind of narrative that gets $100M+ valuations, not $8M OTC caps.
8. A Pathway to NASDAQ (Without a Reverse Split)
The spin‑off can file an S‑1 and uplist directly.
Shareholders would own equity in a company that can actually reach a major exchange.
This bypasses the penny‑stock stigma entirely.
Bottom Line for Shareholders
Here’s the simplest way to think about it:
BIEL shareholders get:
Two assets instead of one
Exposure to a $100M+ private valuation
A clean‑cap‑table company capable of uplisting
Value based on clinical science, not OTC trading
No reverse split required
A chance to participate in high‑margin verticals (vet + neuro)
And all of this is possible because SofPulse already proved the model works.
1. Shareholders Receive a Spin‑Off Dividend
A new private subsidiary (e.g., “BIEL Clinical”) would issue shares directly to existing BIEL shareholders.
You would own:
Your current OTC BIEL shares
Plus equity in a new, clean‑cap‑table company valued far higher
This is the same mechanism SofPulse used to unlock value.
2. Massive Valuation Arbitrage (12× Upside Potential)
OTC values BIEL at ~$8.6M.
SofPulse proved PEMF companies can be valued at $100M+ in private markets.
A spin‑off lets BIEL reprice its assets away from the depressed OTC environment.
Shareholders benefit because the underlying IP is suddenly valued at private‑market multiples.
3. Clean Cap Table = Institutional Money
BIEL’s 24.7B shares block any NASDAQ uplist.
A spin‑off starts fresh with something like 20M shares, instantly investable.
Institutions, family offices, and med‑tech funds will not touch a 25B‑share OTC ticker—but they will invest in a clean, AI‑ready clinical subsidiary.
4. High‑Value Verticals Increase Shareholder Upside
The page highlights two divisions that command premium valuations:
Canine Osteoarthritis (fast‑growing, $800M+ market)
Neurological Recovery / Phantom Limb Pain
Spinning these into a focused entity gives shareholders exposure to markets valued far above consumer retail patches.
5. Clinical Data Supports a $100M+ Valuation
Shareholders benefit because BIEL already has the “hard science” needed to justify a premium valuation:
Stanford Hand Arthritis Study (2025) showed statistically significant pain reduction (p=0.02).
Canine OA studies (2024–2025) position BIEL as a competitor to high‑priced biologics like Librela—without the side‑effects.
This clinical foundation is exactly what private investors pay up for.
6. Crowdfunding Becomes a Growth Engine
SofPulse raised $201k+ by pitching a mission (“ending opioid addiction”).
BIEL has 500,000+ users—a built‑in investor base.
Shareholders benefit because crowdfunding:
Raises capital without toxic dilution
Establishes a high private valuation
Creates a marketing flywheel for the new entity
7. The Narrative Shift Boosts Valuation
Right now, BIEL is valued like a company selling $30 patches.
The spin‑off reframes the story as:
“A $1.25B annual reimbursement opportunity in hospitals and insurance.”
That’s the kind of narrative that gets $100M+ valuations, not $8M OTC caps.
8. A Pathway to NASDAQ (Without a Reverse Split)
The spin‑off can file an S‑1 and uplist directly.
Shareholders would own equity in a company that can actually reach a major exchange.
This bypasses the penny‑stock stigma entirely.
Bottom Line for Shareholders
Here’s the simplest way to think about it:
BIEL shareholders get:
Two assets instead of one
Exposure to a $100M+ private valuation
A clean‑cap‑table company capable of uplisting
Value based on clinical science, not OTC trading
No reverse split required
A chance to participate in high‑margin verticals (vet + neuro)
And all of this is possible because SofPulse already proved the model works.
2
